Records containing: Multiple Sclerosis (MS)
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2017-06-06Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2017-05-25An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2016-12-29Alternative Treatment Paradigm for Natalizumab Trial
-
CLINICAL_TRIALS study record update · 2016-02-12Prevalence of Chronic Cerebrospinal Venous Insufficiency in Patients With Multiple Sclerosis and Other Neurological Diseases. An Ultrasound, Blinded, Case-Controlled, Centralized Reading Assessment
-
CLINICAL_TRIALS study record update · 2015-10-28Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2015-02-02Observational Study of the Physical Capacity of Patients With Multiple Sclerosis and Evaluation of the Effects of Usual Rehabilitation in the Day Hospital
-
CLINICAL_TRIALS study record update · 2014-09-16Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
-
CLINICAL_TRIALS study record update · 2014-04-16PRISM Registry: Pseudobulbar Affect Registry Series
-
CLINICAL_TRIALS study record update · 2013-05-27A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers